Clinical Trials for Exelixis

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Study of XB010 in Subjects With Solid Tumors

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Cabozantinib in High Grade Neuroendocrine Neoplasms

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma